SERD-induced inhibition of MDSCs and concurrent actions on CD8+ and CD4+ T-cells promote the interaction of immune checkpoint inhibitors with breast cancer cells and augment the curative effect (10). The gene discussed is CD8A; the disease is breast carcinoma.